 |
Antithrombin III (human) |
|---|---|
| Trade Name | Atnativ |
| Orphan Indication | For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism |
| USA Market Approval | USA |
| USA Designation Date | 1985-02-08 00:00:00 |
| Sponsor | Pharmacia & Upjohn AB;Lindhagensgatan 133, Stockholm; |
